CUREator+ grant

SeeTreat is pleased to announce we are the recipient of the CUREator+ Grant to clinically evaluate and commercialise a new medical technology to enhance breast cancer radiation therapy treatments. The product is expected to improve treatment effectiveness and mitigate risks of complications due to radiation exposure to the heart and other non-target tissues.

This grant will enable key developments towards the commercialisation of a novel medical software for breast cancer radiation therapy which is not only poised to enhance the accuracy of treatment delivery but do so cost-effectively with minimal overheads for the radiotherapy centre.

The Curator+ Grant will see SeeTreat partner with Australian radiotherapy centres for clinical evaluation and pilot use of the medical software supporting validation and pursue regulatory clearance.

About SeeTreat

SeeTreat Medical, is developing AI-enabled software in breast cancer to improve the accuracy and precision of radiation therapy, in turn increasing treatment effectiveness and mitigating risks of complications due to radiation exposure to the heart and other non-target tissues. CUREator+ funding will be used to further advance the development of SeeTreat software technology, complete a clinical trial supporting validation and pursue regulatory clearance.

About CUREator

CUREator is a national biotechnology incubator by Brandon BioCatalyst that supports Australian biomedical research and innovation development. Funded by the Medical Research Future Fund and Australia's national science agency, CSIRO, CUREator provides grant funding programs for opportunities spanning from discovery research to clinical development.

Funding is provided like an investor with clear milestone-driven tranches to achieve key value-adding and de-risking development milestones. CUREator works closely with project teams to guide them through the early development phases, offering scientific and commercial expertise and networks to support projects meeting key outcomes. https://brandonbiocatalyst.com/cureator/

About ANDHealth

ANDHealth is Australia's only organisation specialising in commercialising evidence-based digital health technologies. We work with Australian digital health companies to commercialise and scale their clinical-grade technologies through the entire commercialisation pathway, from idea to exit.

ANDHealth's investment readiness program suite and non-dilutive investment programs prepare companies for institutional investment and global enterprise customers and have been proven to positively impact both the number and maturity of companies in the Australian evidence-based digital and connected health sector. Since 2018, ANDHealth has supported over 900 high-growth-potential digital health companies across Australia and delivered over 2,400 hours of direct programming to over 1,680 participants. https://www.andhealth.com.au

About Brandon BioCatalyst and Brandon Capital

Brandon Capital is Australasia's leading life science venture capital firm, with a solid global presence supported by key partnerships and team members across the US and UK. Brandon Capital supports life science companies from early-stage seed investment to expansion capital from proof-of-concept to commercialisation. Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology that improve health and save lives. https://brandonbiocatalyst.com/ and https://brandoncapital.vc/